Tarsus Pharmaceuticals, Inc.
TARS · XNASCIK 1819790fmd_0795GCWMV71Q5CE0F70A7F9FW7Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 32 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 57 | 26 | 17 | 183 | 451 |
| Research and development | – | 3 | 19 | 42 | 43 | 50 | 53 | 64 |
| Selling, general and administrative | – | – | – | – | 45 | 109 | 237 | 427 |
| Total operating expenses | – | 4 | 27 | 69 | 89 | 161 | – | – |
| Operating income | – | (4) | (27) | (12) | (63) | (143) | (121) | (71) |
| Interest expense | – | – | – | 0 | 2 | 3 | 8 | 9 |
| Other non-operating income (expense) | – | (0) | 0 | (2) | 1 | 7 | 5 | 7 |
| Income before taxes | – | – | (27) | (14) | (62) | (136) | (116) | (64) |
| Income tax expense | – | 0 | 0 | 0 | (0) | 0 | 0 | 2 |
| Net income from continuing operations | – | – | (27) | (14) | (62) | (136) | (116) | (66) |
| Net income | (1) | (5) | (27) | (14) | (62) | (136) | (116) | (66) |